These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 24441281)

  • 1. Advances in small bowel neuroendocrine neoplasia.
    Banck MS; Beutler AS
    Curr Opin Gastroenterol; 2014 Mar; 30(2):163-7. PubMed ID: 24441281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
    Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK; Fong MK; Iyer R
    Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Established clinical use of octreotide and lanreotide in oncology.
    Oberg K
    Chemotherapy; 2001; 47 Suppl 2():40-53. PubMed ID: 11275701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.
    Kidd M; Drozdov I; Joseph R; Pfragner R; Culler M; Modlin I
    Cancer; 2008 Aug; 113(4):690-700. PubMed ID: 18618499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
    Igaz P
    Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genomic landscape of small intestine neuroendocrine tumors.
    Banck MS; Kanwar R; Kulkarni AA; Boora GK; Metge F; Kipp BR; Zhang L; Thorland EC; Minn KT; Tentu R; Eckloff BW; Wieben ED; Wu Y; Cunningham JM; Nagorney DM; Gilbert JA; Ames MM; Beutler AS
    J Clin Invest; 2013 Jun; 123(6):2502-8. PubMed ID: 23676460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
    Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
    Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
    Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues.
    Khagi S; Saif MW
    JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
    Ryan P; McBride A; Ray D; Pulgar S; Ramirez RA; Elquza E; Favaro JP; Dranitsaris G
    J Oncol Pharm Pract; 2019 Sep; 25(6):1425-1433. PubMed ID: 30924737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
    Aparicio T; Ducreux M; Baudin E; Sabourin JC; De Baere T; Mitry E; Schlumberger M; Rougier P
    Eur J Cancer; 2001 May; 37(8):1014-9. PubMed ID: 11334727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.
    Dawod M; Gordoa TA; Cives M; De Mestier L; Crona J; Spada F; Oberg K; Pavel M; Lamarca A
    Curr Treat Options Oncol; 2021 Jun; 22(8):73. PubMed ID: 34185197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptors: from signaling to clinical practice.
    Theodoropoulou M; Stalla GK
    Front Neuroendocrinol; 2013 Aug; 34(3):228-52. PubMed ID: 23872332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.